middle.news
Neuren’s Record Year Sparks Bold Phase 3 Push for Neurodevelopmental Drug
1:35am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Neuren’s Record Year Sparks Bold Phase 3 Push for Neurodevelopmental Drug
1:35am on Monday 2nd of June, 2025 AEST
Key Points
Record A$166 million comprehensive income in 2024
DAYBUE US net sales reached US$348 million with growing patient base
Positive Phase 2 results for NNZ-2591 across multiple neurodevelopmental disorders
Commencement of Phase 3 trial for Phelan-McDermid syndrome planned for mid-2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE